{"organizations": [], "uuid": "8f4afde7237e81893a92c04d880f2dcdeb97e070", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alder-announces-250-million-commit/brief-alder-announces-250-million-committed-equity-financing-idUSASB0C039", "country": "US", "domain_rank": 408, "title": "BRIEF-Alder Announces $250 Million Committed Equity Financing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.936, "site_type": "news", "published": "2018-01-08T21:08:00.000+02:00", "replies_count": 0, "uuid": "8f4afde7237e81893a92c04d880f2dcdeb97e070"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alder-announces-250-million-commit/brief-alder-announces-250-million-committed-equity-financing-idUSASB0C039", "ord_in_thread": 0, "title": "BRIEF-Alder Announces $250 Million Committed Equity Financing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fina", "sentiment": "negative"}, {"name": "alder biopharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING * ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT\n* ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDERâ€˜S EUROPEAN PATENT SETTLEMENT\n* ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:08:00.000+02:00", "crawled": "2018-01-09T17:18:53.010+02:00", "highlightTitle": ""}